MindWalk Holdings Corp. (HYFT) Form 6-K — Oct 21, 2026
MindWalk Holdings (NASDAQ: HYFT) published a white paper showing its LensAI immunogenicity screening ran across 890,634 antibody sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by AMD EPYC processors. The benchmark showed up to 43% lower cost per sequence and 37% faster performance versus a comparable Intel-based configuration, which the company says lowers its cost of delivery and supports margin as enterprise platform agreements move it toward contracted, recurring revenue.
Key figures
- Flab runtime
- 4 hours 41 minutes
- Hyft patterns
- 660 million
- Humanness step
- roughly one minute for 6,220 sequences on a single 64-core machine
- Plabdab runtime
- 2 hours 12 minutes
- C8a speed gain pct
- 35
- Hyft relationships
- 25 billion
- C8a cost reduction pct
- 29
- Sequences screened flab
- 890634
- Speed gain vs intel pct
- 37
- Sequences screened plabdab
- 348550
- Therapeutic antibody study
- 197 of 217 (~91%) classified with anti-drug antibody incidence risk greater than 30%
- Cost reduction vs intel pct
- 43
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.